+91 789 2456 581 | info@nckpharma.com

Please sign in first

Username

Password

Lost Your Password?

Not a member?

Please simply create an account before buying/booking any courses.

Create an account for free!

Home
- About Us
NCK services
Course List
Admission Process
Knowledge Base
Contact

Home
- About Us
NCK services
Course List
Admission Process
Knowledge Base
Contact

Pharma News

Keep updating your pharma knowledge

24 Sep 2017

What are the major differences between – Breakthrough Therapy Designation Vs. Fast Track Designation Vs. Priority Review Designation Vs. Accelerated Approval

/

Posted Byadmin

/

Comments0

/

TagsAccelerated Approval, Breakthrough Therapy designation, Fast Track designation, FDA grants Priority Review for potential new indication for Brilinta, priority review, Priority Review Designation, usfda accelerated approval

Here is a quick comparison of the USFDA drug development expedited programs. This may help you to distinguishing all of them effectively.

Related Articles

Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
Quick look into Roche’s Tecentriq US FDA priority review grant
USFDA approved first drug for spinal muscular atrophy
Kite Pharma’s axicabtagene got US FDA priority review status to treat NHL
USFDA approved new drug Rubraca, rucaparib

European approval for Roche’s tocilizumab for the treatment of giant cell arteritis (GCA)

USFDA approval of Verzenio to treat certain advanced/metastatic breast cancers

About Post Author

admin

Leave a Reply Cancel Reply

Search With Term

Recent Industry Update

Top 10 Generic Company Globally in 2018 (by revenue)
Top 10 Global Pharmaceutical Company in 2018
Take a self competency test in authorized generics
GSK’s Shingrix received chinese approval for shingles vaccine
Bayer to launch Baycox Iron injection combination in Europe
Health Canada approves Biocon and Mylan’s trastuzumab biosimilar ‘Ogivri’ for HER2-positive cancers
Case Study – A close look into Eli Lilly’s pricing strategy for Insulin Lispro injection in US market
Takeda, Frazier Healthcare Partners to launch Phathom Pharma
Can a new drug rejected by USFDA, can get EU approval?
Novatis’s Xiidra acquisition from Takeda for USD 5.3 billion
FDA approval of first medical device for treatment of ADHD
Sanofi’s Praluent got much needed boost with USFDA new indication approval
Calixar licensing agreement with Regeneron
Sandoz licensing agreement with EirGenix to commercialize trastuzumab biosimilar
Glenmark to introduce SGLT2 inhibitor Remogliflozin in India by licesning collaboration with BHV Pharma
Drug Department asking for documents to be notarizerd. What does it means? How documents should be notarized?
Amedment in Schedule-V of D&C Rules: Revise ‘free salicylic acid’ content in drugs containing aspirin [CDSCO]
Plenity, weight management drug, received USFDA approval
Roche to launch emicizumab (Hemlibra) in India for people with haemophilia A on World Haemophilia Day
Emcure launched first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) in India
DRL sells brand Sernivo; grants Promiseb and Trianex US marketing rights to Encore Dermatology
J&J disinvest ASP business to Fortive Corporation for $2.8 billion
Novartis’ Cosentyx received CFDA (Chainese) approval to treat adults with plaque psoriasis
Why user documents asked while submitting trademark for registration?
How forced degradation can be achieved?
What is ANOVA method?
What is a Stability-indicating assay method?
CDSCO rejects Cipla’s application for marketing US-based MannKind Corporation’s inhaled insulin, branded Afrezza; Local climical trial is compulsory
Check Your Competency in Data Integrity
Novartis’s Multiple Sclerosis Drug Mayzent received USFDA approval

Monthly Archieves

Subscribe to NCK Newsline

Enter your email address:

Delivered by FeedBurner

Popular 1 Year Courses

KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
KPE-C-001 KPE’s Advance Diploma in Pharmaceutical Product Management
KPE-C-003 KPE’s Advance Diploma in Drug Regulatory Affairs
KPE-C-004 KPE’s Advance Diploma in Pharma Marketing
KPE – C- 009 KPE’s Advance Diploma in Pharmacovigilance
KPE-C-005 KPE’s Advance Diploma in Pharmaceutical Production management
KPE-C-08 KPE’s Advance Diploma in Pharmaceutical Strategic Business Management

Javascript is disabled

Javascript is disabled on your browser. Please enable it in order to use this form.

Loading

Query

First Name

Last Name

Email Address

Your Query *

Write Here

6 plus 4 equals?*

Prove you are a human

Write here

Your form has been submitted

Thank you %NAME% for the submitting your query/feedback.

Server Side Error

We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.

If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.

TextStatus: undefined
HTTP Error: undefined

Processing your request

Error

Some error has occured.

Disclaimer & Privacy Policy | Terms of Use

Copyright © 2014 - 2015 All Right Reserved - NCK Pharma Solution Private Limited

This website uses cookies to improve your learning experience. Ok Privacy Policy

Privacy & Cookies Policy

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests

etc.